Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company’s subscriber base reached 2.2 million ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ plan to combine all its dermatology services into one main ...

Shares of HIMS stock opened at $36.01 on Thursday. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to ...

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

Read Our Latest Research Report on HIMS Hims & Hers Health Stock Up 4.7 % Shares of NYSE HIMS opened at $36.01 on Friday. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of ...

Among today’s creative highlights, Clorox brought in neuroscientists to demonstrate some surprising data about how cleaning ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against the other skincare stocks. According to NielsenIQ, the global beauty market is expected to ...